Aim: To investigate the incidence of dyslipidemia (hypertriglyceridemia and hypercholesterolemia) in patients treated with antipsychotics of new generation compared to conventional therapy.
Methods: This retrospective study included 116 chronic psychiatric patients divided into two groups: a test group who were on treatment with antipsychotics of the new generation and a control group who were treated with classical antipsychotics. Laboratory and vital parameters were monitored in a group of patients who were treated with new generation antipsychotics (clozapine, olanzapine, risperidone), as well as in the group of patients who were treated with classical antipsychotics (promazine, levopromazin,haloperidol, fluphenazine).
Results: Mean triglyceride level in the test group was 3.13 mmol/L, and for the control group, 2.28 mmol/L, while the mean value for cholesterol test group was 6.12 mmol/L, and for the control group, 5.85 mmol/L. The average age of the test group was 49.6 years, while the control group was 51.47 years. There was a statistical significance in triglycerides (p = 0.004), while the cholesterol (p = 0.239) and age (p = 0.356) had no statistical significance in the test group compared to the patients who were treated by the new generation of antipsychotics, and the control group of patients who were treated with antipsychotics.
Conclusion: Dyslipidemia in the form of hypertriglyceridemia occurs more frequently in patients on therapy with the new generation of antipsychotics compared to patients treated with conventional therapy. Hypercholesterolemia as a form of dyslipidemia had not been proven as significantly frequent during the therapy with new antipsychotics in relation to classical antipsychotic treatment.